XXXX . The prognostic significance of @entity5 differentiation.

@entity5 @entity1 @entity5426
@entity5426 appears to be a heterogeneous group of @entity5 morphologically, in which growth pattern or grade is an important prognostic factor. In this report, 63 @entity1 whose slides were seen in consultation and/or who were treated at Memorial Sloan-Kettering Cancer Center (MSKCC) are described. Included are 32 MSKCC @entity1 from an earlier study (with additional follow-up for 15 who are alive) and 31 new cases. Twenty-five (40%) @entity1 had low-grade (Type I) lesions (including the only @entity1 in the series), 12 (19%) @entity1 had intermediate-grade (Type II) tumors, and 26 (41%) @entity1 had high-grade (Type III) @entity5426 . Because prognosis is significantly related to the type of @entity5426 , the lesion should be thoroughly studied microscopically to establish @entity5 type. Estimated probabilities of disease-free survival 5 years after initial treatment were as follows: Type I: 76%; Type II: 70%; and Type III: 15%. The median length of disease-free survival also was related to @entity5 type (Type I: greater than 15 years; Type II: greater than 12 years; and Type III: 15 months). Pretreatment duration of the lesion and @entity5 size were not significantly related to the risk of recurrence or to survival. Total mastectomy is recommended for most mammary @entity5426 . Adjuvant chemotherapy was used in 31 of 63 (49%) @entity1 and, in this group, recurrences developed in 14 (45%) @entity1 . Among 32 (51%) @entity1 not treated with adjuvant chemotherapy, 18 (56%) had recurrences. Whereas the few long-term survivors with @entity5 received adjuvant chemotherapy, recurrences developed in most @entity1 with comparable lesions who were given this treatment. Because @entity5426 has a poor prognosis, such treatment may be appropriate for these @entity1 . We were unable to demonstrate that adjuvant chemotherapy significantly improved prognosis for @entity1 with @entity5 , although recurrences tended to be less frequent among treated @entity1 .
